Comparison of bevacizumab and ranibizumab in age-related macular degeneration:a systematic review and meta-analysis
<b>AIM:</b> To compare the effectiveness and safety between bevacizumab and ranibizumab in the treatment of age-related macular degeneration (AMD) through a systematic review and meta-analysis.<b>METHODS:</b>We performed a comprehensive search of randomized controlled trials...
Main Authors: | , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Press of International Journal of Ophthalmology (IJO PRESS)
2014-04-01
|
Series: | International Journal of Ophthalmology |
Subjects: | |
Online Access: | http://www.ijo.cn/en_publish/2014/2/20140230.pdf |
id |
doaj-928d9d47a4024676bd8f620358e1dca6 |
---|---|
record_format |
Article |
spelling |
doaj-928d9d47a4024676bd8f620358e1dca62020-11-24T22:28:54ZengPress of International Journal of Ophthalmology (IJO PRESS)International Journal of Ophthalmology2222-39592227-48982014-04-017235536410.3980/j.issn.2222-3959.2014.02.30Comparison of bevacizumab and ranibizumab in age-related macular degeneration:a systematic review and meta-analysisXiao-Yu Zhang0Xiao-Fan Guo1Shao-Dan Zhang2Jing-Na He3Cao-Yu Sun4Yin Zou5Han-Si Bi6Yang Qu7Department of Ophthalmology, the Fourth People’s Hospital of Shenyang, Shenyang 110031, Liaoning Province, China<br>Department of Cardiology, the First Hospital of China Medical University, Shenyang 110001, Liaoning Province, ChinaDepartment of Ophthalmology, the Fourth People’s Hospital of Shenyang, Shenyang 110031, Liaoning Province, China<br>Department of Ophthalmology, the Fourth People’s Hospital of Shenyang, Shenyang 110031, Liaoning Province, China<br>Department of Ophthalmology, the Fourth People’s Hospital of Shenyang, Shenyang 110031, Liaoning Province, China<br>Department of Ophthalmology, the Fourth People’s Hospital of Shenyang, Shenyang 110031, Liaoning Province, China<br>Department of Ophthalmology, the Fourth People’s Hospital of Shenyang, Shenyang 110031, Liaoning Province, China<br>Department of Ophthalmology, the Fourth People’s Hospital of Shenyang, Shenyang 110031, Liaoning Province, China<br><b>AIM:</b> To compare the effectiveness and safety between bevacizumab and ranibizumab in the treatment of age-related macular degeneration (AMD) through a systematic review and meta-analysis.<b>METHODS:</b>We performed a comprehensive search of randomized controlled trials (RCTs), non-RCTs, case-control and cohort studies that compared bevacizumab and ranibizumab using PubMed and the Cochrane Library. After the related data were extracted by two investigators independently, pooled weighted mean differences (WMDs) and risk ratios (RRs) with 95% confidence intervals (CIs) were estimated using a random-effects or a fixed-effects model.<b>RESULTS:</b>A total of four RCTs involving 1927 patients and eleven retrospective case series involving 2296 patients were included. For the primary outcomes, no significant differences were found between ranibizumab group and bevacizumab group in visual acuity (WMD:-0.04; 95%CI:-0.08 to 0.00; <i>P=</i>0.06), best corrected visual acuity (WMD:-0.05; 95%CI:-0.10 to 0.00; <i>P=</i>0.05), retina thickness (WMD:-4.69; 95%CI:-13.15 to 3.76; <i>P=</i>0.86) and foveal thickness (WMD:10.91; 95%CI:-14.73 to 36.56; <i>P=</i>0.40). The pooled analyses in the evaluation of safety showed that compared to bevacizumab, ranibizumab was associated with decreased risks of ocular inflammation (RR:0.45; 95% CI:0.23 to 0.89; <i>P=</i>0.02) and venous thrombotic events (RR:0.27; 95%CI:0.08 to 0.89; <i>P=</i>0.03). However, there were no significant differences observed in deaths (<i>P=</i>0.69) and arterial thromboembolic events (<i>P=</i>0.71) between the two groups.<b>CONCLUSION:</b>With equal clinical efficacy, ranibizumab was found to be associated with less adverse events compared to bevacizumab, indicating that ranibizumab might be a safer management.http://www.ijo.cn/en_publish/2014/2/20140230.pdfage-related macular degenerationbevacizumabranibizumabranibizumab |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Xiao-Yu Zhang Xiao-Fan Guo Shao-Dan Zhang Jing-Na He Cao-Yu Sun Yin Zou Han-Si Bi Yang Qu |
spellingShingle |
Xiao-Yu Zhang Xiao-Fan Guo Shao-Dan Zhang Jing-Na He Cao-Yu Sun Yin Zou Han-Si Bi Yang Qu Comparison of bevacizumab and ranibizumab in age-related macular degeneration:a systematic review and meta-analysis International Journal of Ophthalmology age-related macular degeneration bevacizumab ranibizumab ranibizumab |
author_facet |
Xiao-Yu Zhang Xiao-Fan Guo Shao-Dan Zhang Jing-Na He Cao-Yu Sun Yin Zou Han-Si Bi Yang Qu |
author_sort |
Xiao-Yu Zhang |
title |
Comparison of bevacizumab and ranibizumab in age-related macular degeneration:a systematic review and meta-analysis |
title_short |
Comparison of bevacizumab and ranibizumab in age-related macular degeneration:a systematic review and meta-analysis |
title_full |
Comparison of bevacizumab and ranibizumab in age-related macular degeneration:a systematic review and meta-analysis |
title_fullStr |
Comparison of bevacizumab and ranibizumab in age-related macular degeneration:a systematic review and meta-analysis |
title_full_unstemmed |
Comparison of bevacizumab and ranibizumab in age-related macular degeneration:a systematic review and meta-analysis |
title_sort |
comparison of bevacizumab and ranibizumab in age-related macular degeneration:a systematic review and meta-analysis |
publisher |
Press of International Journal of Ophthalmology (IJO PRESS) |
series |
International Journal of Ophthalmology |
issn |
2222-3959 2227-4898 |
publishDate |
2014-04-01 |
description |
<b>AIM:</b> To compare the effectiveness and safety between bevacizumab and ranibizumab in the treatment of age-related macular degeneration (AMD) through a systematic review and meta-analysis.<b>METHODS:</b>We performed a comprehensive search of randomized controlled trials (RCTs), non-RCTs, case-control and cohort studies that compared bevacizumab and ranibizumab using PubMed and the Cochrane Library. After the related data were extracted by two investigators independently, pooled weighted mean differences (WMDs) and risk ratios (RRs) with 95% confidence intervals (CIs) were estimated using a random-effects or a fixed-effects model.<b>RESULTS:</b>A total of four RCTs involving 1927 patients and eleven retrospective case series involving 2296 patients were included. For the primary outcomes, no significant differences were found between ranibizumab group and bevacizumab group in visual acuity (WMD:-0.04; 95%CI:-0.08 to 0.00; <i>P=</i>0.06), best corrected visual acuity (WMD:-0.05; 95%CI:-0.10 to 0.00; <i>P=</i>0.05), retina thickness (WMD:-4.69; 95%CI:-13.15 to 3.76; <i>P=</i>0.86) and foveal thickness (WMD:10.91; 95%CI:-14.73 to 36.56; <i>P=</i>0.40). The pooled analyses in the evaluation of safety showed that compared to bevacizumab, ranibizumab was associated with decreased risks of ocular inflammation (RR:0.45; 95% CI:0.23 to 0.89; <i>P=</i>0.02) and venous thrombotic events (RR:0.27; 95%CI:0.08 to 0.89; <i>P=</i>0.03). However, there were no significant differences observed in deaths (<i>P=</i>0.69) and arterial thromboembolic events (<i>P=</i>0.71) between the two groups.<b>CONCLUSION:</b>With equal clinical efficacy, ranibizumab was found to be associated with less adverse events compared to bevacizumab, indicating that ranibizumab might be a safer management. |
topic |
age-related macular degeneration bevacizumab ranibizumab ranibizumab |
url |
http://www.ijo.cn/en_publish/2014/2/20140230.pdf |
work_keys_str_mv |
AT xiaoyuzhang comparisonofbevacizumabandranibizumabinagerelatedmaculardegenerationasystematicreviewandmetaanalysis AT xiaofanguo comparisonofbevacizumabandranibizumabinagerelatedmaculardegenerationasystematicreviewandmetaanalysis AT shaodanzhang comparisonofbevacizumabandranibizumabinagerelatedmaculardegenerationasystematicreviewandmetaanalysis AT jingnahe comparisonofbevacizumabandranibizumabinagerelatedmaculardegenerationasystematicreviewandmetaanalysis AT caoyusun comparisonofbevacizumabandranibizumabinagerelatedmaculardegenerationasystematicreviewandmetaanalysis AT yinzou comparisonofbevacizumabandranibizumabinagerelatedmaculardegenerationasystematicreviewandmetaanalysis AT hansibi comparisonofbevacizumabandranibizumabinagerelatedmaculardegenerationasystematicreviewandmetaanalysis AT yangqu comparisonofbevacizumabandranibizumabinagerelatedmaculardegenerationasystematicreviewandmetaanalysis |
_version_ |
1725745770094657536 |